07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Remogliflozin etabonate: Additional Phase IIb data

Additional data from a double-blind, dose-ranging, placebo- and pioglitazone-controlled, international Phase IIb trial in 336 treatment-naive patients with Type II diabetes showed that twice-daily 50, 100, 250, 500 and 1,000 mg remogliflozin etabonate improved insulin...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

BHV Pharma, Islet Sciences deal

Islet Sciences and BHV Pharma will terminate a proposed merger to form Avogenx Inc. in favor of a licensing deal granting Islet exclusive rights to develop and commercialize BHV’s remogliflozin etabonate outside of Japan, Korea,...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

BHV Pharma, Libbs deal

BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to develop and commercialize remogliflozin etabonate. BHV will receive $1.5 million up front and Libbs will fund "a substantial portion" of BHV's Phase...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Remogliflozin etabonate: Phase IIb data

BHV and Islet Sciences Inc. (OTCBB:ISLT, New York, N.Y.) reported data from a pair of double-blind, dose-ranging, placebo- and pioglitazone-controlled Phase IIb trials in 563 treatment-naïve patients with Type II diabetes showing that all doses...
23:44 , Apr 16, 2014 |  BC Extra  |  Clinical News

BHV, Islet report Phase IIb data for SGLT2 inhibitor

BHV Pharma Inc. (Research Triangle Park, N.C.) and Islet Sciences Inc. (OTCBB:ISLT) reported data on Wednesday from a pair of double-blind, dose-ranging Phase IIb trials evaluating remogliflozin etabonate ( BHV091009 ) in treatment-naïve patients with...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

BHV Pharma, Islet Sciences deal

Islet Sciences signed a letter of intent to acquire BHV Pharma in a stock deal. Islet Sciences will issue BHV shareholders 30 million shares of Islet Sciences common stock, valued at $12 million based on...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Islet Sciences management update

Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y.   Business: Endocrine/Metabolic, Transplant   Hired: James Green as CEO, formerly chairman and CEO of BHV Pharma Inc. ; and William Wilkison as COO, formerly a director and...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

Remogliflozin etabonate: Phase I data

An open-label, U.S. Phase I trial showed that there was no significant increase in area under the curve (AUC) or half-life of remogliflozin in 17 subjects with mild or moderate renal impairment following treatment with...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Company News

BHV Pharma, Kissei Pharmaceutical deal

BHV received exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize Kissei's Remogliflozin etabonate. The selective sodium-glucose cotransporter 2 (SGLT2) inhibitor is in Phase IIb testing to treat Type II diabetes. Kissei...
01:37 , Jan 7, 2011 |  BC Extra  |  Company News

Kissei, BHV in deal for diabetes candidate

Kissei Pharmaceutical Co. Ltd. (Tokyo:4547) granted BHV Pharma Inc. (Research Triangle Park, N.C.) exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize Remogliflozin etabonate. The selective sodium-glucose cotransporter 2 (SGLT2) inhibitor is...